Group 1 - The Hang Seng Biotechnology ETF (159615) has risen by 2.92% as of August 13, 2025, with an active trading volume of 1.26 billion yuan and a turnover rate of 36.28% [1] - The Hang Seng Biotechnology Index, which the ETF tracks, increased by 3.39%, with notable gains from constituent stocks such as CanSino Biologics (up 8.52%), WuXi AppTec (up 7.34%), and Innovent Biologics (up 6.07%) [1] - As of August 12, the ETF saw a net inflow of 2.5381 million yuan, with a total net inflow of 20.5331 million yuan over the last five trading days, indicating a positive investment sentiment [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drug names passing the commercial insurance innovative drug directory review [1] - High-priced innovative drugs, including CAR-T cancer treatment, are seeking inclusion in the commercial insurance innovative drug directory, aiming for diversified payment options for innovative drugs [1] - CITIC Securities expresses a long-term positive outlook on the innovative drug sector, emphasizing the importance of innovation-driven strategies, internationalization, and reforms in outpatient marketing models [1] Group 3 - The Hang Seng Biotechnology Index reflects the overall performance of the largest 50 biotechnology companies listed in Hong Kong, including major stocks like BeiGene, Innovent Biologics, and WuXi Biologics [2]